To assess the efficacy of the pVAX14 vaccine, we first used, as a proof of concept, the APL mouse model [13] where we previously identified and documented the enhanced survival induced by the specific vaccine PML-RARA in combination with ATRA compared with either ATRA alone or ATRA+pcDNA3 empty vector [8]. The gene discussed is PML; the disease is acute promyelocytic leukemia.